TY - JOUR
AU - T. Chen
AU - I. Iskandar
AU - R. Parisi
AU - M. Pierce
AU - C. Tower
AU - C. Kleyn
AU - C. Griffiths
AU - D. Ashcroft
AD - Centre for Pharmacoepidemiology and Drug Safety, Division of Pharmacy and Optometry, School of Health Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, England, United Kingdom.
Centre for Occupational and Environmental Health, Division of Population Health, Health Services Research and Primary Care, School of Health Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, England, United Kingdom.
Division of Informatics, Imaging and Data Sciences, Manchester Academic Health Sciences Centre, School of Health Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, England, United Kingdom.
Centre for Women's Mental Health, Division of Psychology and Mental Health, School of Health Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, England, United Kingdom.
Division of Obstetrics, St Mary's Hospital, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, England, United Kingdom.
Centre for Dermatology Research, Salford Royal NHS Foundation Trust, The University of Manchester, Manchester Academic Health Science Centre, National Institute for Health and Care Research (NIHR) Manchester Biomedical Research Centre, Manchester, England, United Kingdom.
National Institute for Health and Care Research (NIHR) Greater Manchester Patient Safety Translational Research Centre, Manchester Academic Health Science Centre, The University of Manchester, Manchester, England, United Kingdom.
AN - 37285130
BT - JAMA Dermatol
C2 - PMC10248813 Almirall, Celgene, Eli Lilly, Galderma, GSK, Leo Pharma, Janssen, Novartis, Pfizer, and UCB Pharma; grants from Almirall, Amgen, Celgene, Eli Lilly, Janssen, Novartis, Pfizer, and UCB Pharma; and nonfinancial support from Eli Lilly, Leo Pharma, Janssen, and UCB Pharma outside the submitted work. Prof Griffiths reported grants from the LEO Foundation and the International League of Dermatological Societies during the conduct of the study, as well as grants from Almirall and UCB Pharma and personal fees from AbbVie, Boehringer Ingelheim, Evelo Bioscience, Inmagene, Eli Lilly, Janssen, Novartis, GSK, Ono Pharmaceutical, and Bristol Myers Squibb outside the submitted work. Prof Ashcroft reported grants from Abbvie, Almirall, Celgene, Eli Lilly, Janssen, Novartis, UCB Pharma and the LEO Foundation during the conduct of the study. No other disclosures were reported.
DO - 10.1001/jamadermatol.2023.1400
DP - NLM
ET - 2023/06/07
LA - eng
N1 - 2168-6084
Chen, Teng-Chou
Iskandar, Ireny Y K
Parisi, Rosa
Pierce, Matthias
Tower, Clare
Kleyn, C Elise
Griffiths, Christopher E M
Ashcroft, Darren M
Global Psoriasis Atlas
Journal Article
United States
JAMA Dermatol. 2023 Jun 7:e231400. doi: 10.1001/jamadermatol.2023.1400.
PY - 2023
SN - 2168-6068 (Print)
2168-6068
T2 - JAMA Dermatol
TI - Fertility Trends and Adverse Pregnancy Outcomes in Female Patients With Psoriasis in the UK
ER -